This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Zimmer Biomet is a leading musculoskeletal healthcare company that designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants; and related surgical products. With operations in over 25 countries, Zimmer markets products in more than 100 countries. In 2015, Zimmer Holdings, Inc. (the legacy company) acquired Biomet, Inc. to form a new consolidated company.
Here's Why You Should Retain Charles River (CRL) Stock Now
by Zacks Equity Research
Charles River's (CRL) share price is likely to grow, backed by strategic acquisitions and the DSA segment's strength.
LabCorp (LH) Base Business Growth Strong, Margin Pressure Stays
by Zacks Equity Research
LabCorp (LH) is progressing well with its planned spin-off of the Clinical Development business, which is expected to be completed in mid-2023.
Here's Why Investors Should Retain Henry Schein (HSIC) for Now
by Zacks Equity Research
Henry Schein (HSIC) is expected to witness a favorable share price movement, led by optimism surrounding the performance of the dental business and strategic buyouts.
Abbott (ABT) EPD Business Grows Strong, Macro Issues Stay
by Zacks Equity Research
Abbott (ABT) continues to make good progress, increasing manufacturing production and recovering market share in the Nutrition business.
Zacks Industry Outlook Highlights Stryker, Boston Scientific, Zimmer Biomet and Insulet
by Zacks Equity Research
Stryker, Boston Scientific, Zimmer Biomet and Insulet are part of the Zacks Industry Outlook article.
Here's Why Investors Should Retain Syneos Health (SYNH) for Now
by Zacks Equity Research
Syneos Health's (SYNH) share price movement is expected to be favorable due to the strength of the company's Syneos One portfolio and several value-added partnership deals.
4 Medical Products Stocks to Capitalize on the Industry's Recovery
by Indrajit Bandyopadhyay
Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should lend support to the Zacks Medical-Products industry. SYK, BSX, ZBH and PODD are well-poised to gain from the favorable factors.
Encompass Health's (EHC) Q1 Earnings Beat, '23 EPS View Up
by Zacks Equity Research
Encompass Health's (EHC) Q1 results reflect improved patient volumes and higher discharge growth. Management estimates 2023 adjusted EPS within $2.94-$3.23, up from the earlier view of $2.87-$3.16.
What Makes Zimmer Biomet (ZBH) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does Zimmer Biomet (ZBH) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zimmer Biomet (ZBH) Q1 Earnings Beat Estimates, View Raised
by Zacks Equity Research
Each of Zimmer Biomet's (ZBH) geographic segments and product divisions records strong year-over-year sales growth at CER.
Zimmer (ZBH) Reports Q1 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Zimmer (ZBH) give a sense of how its business performed in the quarter ended March 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zimmer Biomet (ZBH) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Zimmer (ZBH) delivered earnings and revenue surprises of 13.86% and 7.39%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Insulet (PODD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Insulet (PODD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZBH or LMAT: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ZBH vs. LMAT: Which Stock Is the Better Value Option?
Zimmer Biomet (ZBH) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Zimmer (ZBH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zimmer Biomet (ZBH) Hits 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Zimmer Biomet's (ZBH) continued business recovery.
Zimmer Biomet (ZBH) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Zimmer Biomet (ZBH) might have faced an upheaval in business, thanks to the global inflationary situation in terms of mounting labor and raw material costs, severe staffing shortages and supply issues.
Here's Why Investors Should Invest in Zimmer Biomet (ZBH) Now
by Zacks Equity Research
Investors are optimistic about Zimmer Biomet (ZBH) on strong elective procedure recovery and commercial execution.
AngioDynamics (ANGO) Q3 Earnings Lag Estimates, FY23 View Cut
by Zacks Equity Research
AngioDynamics (ANGO) registers strong revenue growth in the Med Tech and Med Device businesses in third-quarter fiscal 2023.
ZBH vs. LMAT: Which Stock Is the Better Value Option?
by Zacks Equity Research
ZBH vs. LMAT: Which Stock Is the Better Value Option?
QuidelOrtho (QDEL) Down 4.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
QuidelOrtho (QDEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why Investors Should Buy Zimmer Biomet (ZBH) Now
by Zacks Equity Research
Investors are optimistic about Zimmer Biomet (ZBH) on ongoing business recovery.
Zimmer Biomet (ZBH) Gains From Market Recovery, Global Growth
by Zacks Equity Research
Zimmer Biomet (ZBH) witnesses continued traction across hip products, including the G7 revision system and Avenir Complete primary hip.
ZBH vs. LMAT: Which Stock Is the Better Value Option?
by Zacks Equity Research
ZBH vs. LMAT: Which Stock Is the Better Value Option?
Zacks Industry Outlook Highlights Stryker, Zimmer Biomet and Haemonetics
by Zacks Equity Research
Stryker, Zimmer Biomet and Haemonetics have been highlighted in this Industry Outlook article.